Loading...
Publication
Tirzepatida: um novo tratamento para a obesidade
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 38135 | 1.87 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Em paralelo com o crescente aumento da obesidade a nível mundial, a comunidade científica começou a estudar os agonistas dos recetores do peptídeo 1 semelhante ao glucagon (GLP-1RAs), uma vez que este peptídeo exerce várias ações a nível do seu recetor, presente em múltiplos órgãos. O interesse no polipeptídeo insulinotrópico dependente de glucose (GIP) foi inicialmente negligenciado, no entanto, anos mais tarde provou-se que a administração desta incretina também exercia benefícios ao nível de vários órgãos e tecidos. Posto isto, nos últimos anos, a pesquisa científica da ação sinérgica do GIP e do peptídeo 1 semelhante ao glucagon (GLP-1) intensificou-se após se ter verificado que a administração simultânea das duas incretinas provocava uma diminuição da ingestão de alimentos e um aumento do gasto de energia tendo, assim, resultados favoráveis na redução do peso. Desta forma, foi desenvolvido um agonista duplo dos recetores GIP/GLP-1, denominado twincretin.
A tirzepatida (TZP), uma twincretin, foi desenvolvida pela Lilly and Company com o nome comercial de Mounjaro™, tendo sido aprovada em maio de 2022 pela Administração Federal de Alimentos e Medicamentos (FDA) para o tratamento da diabetes mellitus tipo 2 (DMT2).
Segundo os resultados do ensaio SURPASS-1, com a administração de TZP a redução do peso corporal diminui entre 7,9 a 11,0%, no SURPASS-2 a redução foi de 8,5 a 13,1%, no SURPASS-4 foi de 8,1 a 13,0%, no SURPASS J-mono foi de 7,8 a 13,9% e no SURPASS J-combo entre 5,1 a 10,1% com a administração de 5 mg a 15 mg de TZP semanalmente. Nas pessoas sem DMT2, a administração semanal de TZP nas doses de 5 a 15 mg, para o tratamento da obesidade (SURMOUNT-1) resultou em reduções substanciais no peso corporal (16,5 a 22,4%) ao longo de 72 semanas.
Assim, os ensaios clínicos SURPASS e SURMOUNT-1 sugerem que a TZP está a marcar uma nova era no controlo da DMT2 e/ou da obesidade através do agonismo duplo das hormonas intestinais, uma vez que apresentou resultados muito mais favoráveis em comparação com outros fármacos anti-obesidade já existentes no mercado.
In parallel with the growing increase in obesity worldwide, the scientific community began to study glucagon-like peptide-1 receptor agonists (GLP-1RAs), since glucagon-like peptide-1 (GLP-1) exerts several actions at the level of its receptor, present in multiple organs. The interest in glucose-dependent insulinotropic polypeptide (GIP) was initially neglected, however, years later it was proven that the administration of this incretin also provided benefits at the level of various organs and tissues. That being said, in recent years, scientific research into the synergistic action of GIP and GLP-1 has intensified, after it was found that the simultaneous administration of the two incretins caused a decrease in food intake and an increase in energy expenditure, thus having favorable results in weight reduction. In this way, a dual agonist of the GIP/GLP-1 receptors, called twincretin, was developed. Tirzepatide (TZP), a twincretin, was developed by Lilly and Company under the trade name Mounjaro™, having been approved in May 2022 by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus (T2DM). According to the results of the SURPASS-1 trial, with the administration of TZP, the reduction in body weight varied between 7.9 and 11.0%, in the SURPASS-2 the reduction was from 8.5 to 13.1%, in the SURPASS-4 it was 8.1 to 13.0%, in the SURPASS J-mono it was 7.8 to 13.9% and in the SURPASS J-combo it was 5.1 to 10.1% with administration of 5 mg to 15 mg of TZP weekly. In people without T2DM, weekly administration of TZP at doses of 5 to 15 mg for the treatment of obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5 to 22.4%) over the course of 72 weeks. Therefore, the SURPASS and SURMOUNT-1 clinical trials suggest that TZP is marking a new era in the control of T2DM and/or obesity through double agonism of intestinal hormones, as it presented much more favorable results compared to other anti-obesity drugs already on the market.
In parallel with the growing increase in obesity worldwide, the scientific community began to study glucagon-like peptide-1 receptor agonists (GLP-1RAs), since glucagon-like peptide-1 (GLP-1) exerts several actions at the level of its receptor, present in multiple organs. The interest in glucose-dependent insulinotropic polypeptide (GIP) was initially neglected, however, years later it was proven that the administration of this incretin also provided benefits at the level of various organs and tissues. That being said, in recent years, scientific research into the synergistic action of GIP and GLP-1 has intensified, after it was found that the simultaneous administration of the two incretins caused a decrease in food intake and an increase in energy expenditure, thus having favorable results in weight reduction. In this way, a dual agonist of the GIP/GLP-1 receptors, called twincretin, was developed. Tirzepatide (TZP), a twincretin, was developed by Lilly and Company under the trade name Mounjaro™, having been approved in May 2022 by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus (T2DM). According to the results of the SURPASS-1 trial, with the administration of TZP, the reduction in body weight varied between 7.9 and 11.0%, in the SURPASS-2 the reduction was from 8.5 to 13.1%, in the SURPASS-4 it was 8.1 to 13.0%, in the SURPASS J-mono it was 7.8 to 13.9% and in the SURPASS J-combo it was 5.1 to 10.1% with administration of 5 mg to 15 mg of TZP weekly. In people without T2DM, weekly administration of TZP at doses of 5 to 15 mg for the treatment of obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5 to 22.4%) over the course of 72 weeks. Therefore, the SURPASS and SURMOUNT-1 clinical trials suggest that TZP is marking a new era in the control of T2DM and/or obesity through double agonism of intestinal hormones, as it presented much more favorable results compared to other anti-obesity drugs already on the market.
Description
Keywords
Obesidade GIP GLP-1 Tirzepatida Twincretin Incretinas Medicação anti-obesidade Obesity Tirzepatide Incretins Anti-obesity medication